logo
logo
SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates
Every plan includes:
✓Signal-Driven Leads Based on YOUR ICP
✓Slack + Chrome real-time alerts
✓No duplicates — only new events
INDUSTRY FIRST

Pillar Biosciences Closes $29.7 Million in Series C Financing

May 12, 2020•over 5 years ago

Amount Raised

$29 Million

Round Type

series c

Natick

Description

 Pillar Biosciences, an NGS clinical cancer diagnostics company, today announced the closing of a $29.7 million Series C preferred stock financing. The financing will accelerate the expansion of Pillar's in vitro diagnostic and research use only panels and advance Pillar's global commercial outreach.

Company Information

Company

Pillar Biosciences

Location

Natick, Massachusetts, United States

About

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp®- and PiVAT®-based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.  Learn more at https://pillar-biosciences.com.

FundzWatch™ Score

76
Medium Activity

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech